Pituitary gland: Medical therapy for acromegaly: can we predict response?
- PMID: 19629067
- DOI: 10.1038/nrendo.2009.146
Pituitary gland: Medical therapy for acromegaly: can we predict response?
Abstract
Response to medical therapy for acromegaly is highly variable, with few predictive factors available to help clinicians make informed treatment choices. Researchers in the UK now suggest that prior radiotherapy might influence an individual's response to secondary therapy with dopamine agonists or somatostatin analogs.
Comment on
-
Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues.J Clin Endocrinol Metab. 2009 Apr;94(4):1255-63. doi: 10.1210/jc.2008-1420. Epub 2009 Jan 21. J Clin Endocrinol Metab. 2009. PMID: 19158203
Similar articles
-
Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues.J Clin Endocrinol Metab. 2009 Apr;94(4):1255-63. doi: 10.1210/jc.2008-1420. Epub 2009 Jan 21. J Clin Endocrinol Metab. 2009. PMID: 19158203
-
Efficacy and safety of radiotherapy in acromegaly.Arch Med Res. 2011 Jan;42(1):48-52. doi: 10.1016/j.arcmed.2011.01.004. Arch Med Res. 2011. PMID: 21376263
-
Biochemical assessment and long-term monitoring in patients with acromegaly: statement from a joint consensus conference of the Growth Hormone Research Society and the Pituitary Society.J Clin Endocrinol Metab. 2004 Jul;89(7):3099-102. doi: 10.1210/jc.2003-031138. J Clin Endocrinol Metab. 2004. PMID: 15240576 Review. No abstract available.
-
Consensus statement: medical management of acromegaly.Eur J Endocrinol. 2005 Dec;153(6):737-40. doi: 10.1530/eje.1.02036. Eur J Endocrinol. 2005. PMID: 16322377
-
Current and future medical treatments for patients with acromegaly.Expert Opin Pharmacother. 2016 Aug;17(12):1631-42. doi: 10.1080/14656566.2016.1199687. Epub 2016 Jun 28. Expert Opin Pharmacother. 2016. PMID: 27352098 Review.
Cited by
-
A botulinum toxin-derived targeted secretion inhibitor downregulates the GH/IGF1 axis.J Clin Invest. 2012 Sep;122(9):3295-306. doi: 10.1172/JCI63232. Epub 2012 Aug 1. J Clin Invest. 2012. PMID: 22850878 Free PMC article.
-
STAT3 upregulation in pituitary somatotroph adenomas induces growth hormone hypersecretion.J Clin Invest. 2015 Apr;125(4):1692-702. doi: 10.1172/JCI78173. Epub 2015 Mar 16. J Clin Invest. 2015. PMID: 25774503 Free PMC article.
-
Clinical implications of growth hormone-secreting tumor subtypes.Endocrine. 2012 Aug;42(1):18-28. doi: 10.1007/s12020-012-9660-9. Epub 2012 Mar 21. Endocrine. 2012. PMID: 22434413 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources